

Humanigen, Inc.

08:55 10 Aug 2020

Humanigen gets regulatory nod to begin Phase 3 coronavirus trial of lenzilumab in Brazil

Humanigen Inc (OTCQB:HGEN) announced Monday that Brazilian regulators have granted the company permission to begin a Phase 3 study of its drug lenzilumab on coronavirus (COVID-19) patients in the country.

The study will follow the same protocol approved by the US Food and Drug Administration in April - a randomized, placebo-controlled, double-blind clinical trial format for severe and critical coronavirus patients with a high risk of disease progression.

The study is now set to begin recruiting patients, the company said.

READ: Humanigen appoints experienced healthcare executive, Bob Atwill to newly created role of Head of Asia-Pacific

"COVID-19 is a global crisis and we are committed to offering assistance to patients across the world that are impacted by the pandemic," Humanigen CEO Cameron Durant said in a statement.

"We hope that expanding the study of lenzilumab to research centers in Brazil, a country with surging rates of COVID-19, will offer patients much needed access to a leading COVID-19 therapeutic candidate," he added.

To conduct the trial, Humanigen is working with Clinical Trials & Consulting (CTI), which was recently named the top global contract research organization, the company said.

"Access to clinical trials is critical for healthcare providers in the fight against COVID-19," CTI CEO Timothy Schroeder said. "We are proud to collaborate with our colleagues at Humanigen to extend the reach of the Phase III study of lenzilumab and bring a potential treatment option to those in need."


Brazil has the second-highest reported number of coronavirus cases in the world, behind only the US, according to The New York Times.

Lenzilumab is designed to treat the cytokine storm, an overactive immune system response to the coronavirus that can cause fever and inflammation and potentially lead to organ failure.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

1 Year Share Price Graph



October 2019 April 2020 September 2020

Share Information

Code: HGEN
Listing: OTCQB
Sector: Pharma & Biotech
Website: www.humanigen.com

Company Synopsis:

Humanigen develops biologics to improve CAR-T and other breakthrough oncology treatments. Lenzilumab is a product that has the potential to both improve the efficacy and safety associated with CAR-T therapy in oncology. We are developing lenzilumab in close collaboration with the leading and most experienced centers in the CAR-T field. We are exploring partnerships with established and emerging CAR-T companies.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).